{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:58:38Z","timestamp":1790791118150,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,8,17]],"date-time":"2017-08-17T00:00:00Z","timestamp":1502928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,8,17]],"date-time":"2017-08-17T00:00:00Z","timestamp":1502928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The present study identifies the potential of highly biocompatible SF-GNP nano-conjugate to enhance the chemotherapeutic response to combat drug resistance in cancer cells. We developed a stable colloidal suspension of sorafenib-gold nanoconjugate (SF-GNP) of &lt;10\u2009nm size in aqueous medium for reverting the cancer drug resistance in SF-resistant HepG2 cells in a 3D <jats:italic>ex-vivo<\/jats:italic> model system. <jats:italic>In-vivo<\/jats:italic> biocompatibility assay of SF-GNPs showed absence of systemic toxicological effects including hematological, biochemical and histological parameters. More importantly, the histopathological analysis of vital organs such as liver, brain, lung, kidney and heart showed very least or no sign of inflammation, cell infiltration, necrosis, tissue disorganization or fibrotic reactions after intra-peritoneal administration of SF-GNP nanoconjugates in animals. However, SF-GNP nanoconjugates significantly reduced (&gt;80%) the percentage cell survival and the\u00a0size and\u00a0number of SF resistant solid tumor colonies of HepG2 cells in 3D model system.\u00a0The exposure of SF-GNP nanoconjugate to SF resistant HepG2 cell colonies also provided evidence for\u00a0anti-proliferative effect and reversal of drug resistance by elucidating the molecular regulatory mechanisms of extracellular matrix factor (CD147), tumor growth factor (TGF-\u03b2), hepatoma upregulated protein (hURP) and drug transporter (ABCG-2).<\/jats:p>","DOI":"10.1038\/s41598-017-08878-y","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T10:50:39Z","timestamp":1502448639000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Use of Biocompatible Sorafenib-gold Nanoconjugates for Reversal of Drug Resistance in Human Hepatoblatoma Cells"],"prefix":"10.1038","volume":"7","author":[{"given":"Sandeep Kumar","family":"Vishwakarma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Sharmila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash","family":"Bardia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakkireddy","family":"Chandrakala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Raju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Sravani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. V. S.","family":"Sastry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Aejaz","family":"Habeeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleem Ahmed","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshal","family":"Dhayal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,17]]},"reference":[{"key":"8878_CR1","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1158\/1078-0432.CCR-12-0151","volume":"18","author":"A Villanueva","year":"2012","unstructured":"Villanueva, A. & Llovet, J. M. Second-line therapiesin hepatocellular carcinoma: emergence of resistance to sorafenib. Clin Cancer Res \n                           18, 1824\u20131826 (2012).","journal-title":"Clin Cancer Res"},{"key":"8878_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal, A. et al. Global cancer statistics. CA Cancer J Clin \n                           61, 69\u201390 (2011).","journal-title":"CA Cancer J Clin"},{"issue":"13","key":"8878_CR3","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"2013","author":"C Holohan","year":"2013","unstructured":"Holohan, C., Sandra, V. S., Daniel, B. L. & Patrick, G. J. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer \n                           2013(13), 714\u2013726 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"8878_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrc706","volume":"2","author":"MM Gottesman","year":"2002","unstructured":"Gottesman, M. M., Fojo, T. & Bates, S. E. Multidrug resistance incancer: Role of ATP- dependent transporters. Nat. Rev. Cancer \n                           2, 48\u201358 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"8878_CR5","doi-asserted-by":"crossref","unstructured":"Maeda, H., Wu, J., Sawa, T., Matsumura, Y. & Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release \n                           1 65(1\u20132), 271\u2013284 (2000).","DOI":"10.1016\/S0168-3659(99)00248-5"},{"issue":"9","key":"8878_CR6","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1080\/17425255.2016.1196186","volume":"12","author":"N Mehri","year":"2016","unstructured":"Mehri, N. et al. Nano-based strategies to overcome p-glycoprotein-mediated drug resistance. Expert Opin Drug Metab Toxicol \n                           12(9), 1021\u20131033 (2016).","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"8878_CR7","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.2147\/IJN.S21657","volume":"6","author":"XD Zhang","year":"2011","unstructured":"Zhang, X. D. et al. Size-dependent in vivo toxicity of PEG-coated gold nanoparticles. Int J Nanomed \n                           6, 2071\u20132081 (2011).","journal-title":"Int J Nanomed"},{"issue":"1","key":"8878_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nano.2011.11.001","volume":"8","author":"G Vecchio","year":"2012","unstructured":"Vecchio, G. et al. Mutagenic effects of gold nanoparticles induce aberrant phenotypes in Drosophila Melanogaster. Nanomed \n                           8(1), 1\u20137 (2012).","journal-title":"Nanomed"},{"issue":"10","key":"8878_CR9","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/jat.2865","volume":"33","author":"S Fraga","year":"2013","unstructured":"Fraga, S. et al. Influence of the surface coating on the cytotoxicity, genotoxicity and uptake of gold nanoparticles in human HepG2 cells. J Appl Toxicol \n                           33(10), 1111\u20131119 (2013).","journal-title":"J Appl Toxicol"},{"issue":"3","key":"8878_CR10","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.24199","volume":"53","author":"J Bruix","year":"2011","unstructured":"Bruix, J. & Sherman, M. Management of hepatocellular carcinoma: An update. Hepatol \n                           53(3), 1020\u20131022 (2011).","journal-title":"Hepatol"},{"issue":"7","key":"8878_CR11","doi-asserted-by":"publisher","first-page":"345","DOI":"10.4254\/wjh.v5.i7.345","volume":"5","author":"B Zhai","year":"2013","unstructured":"Zhai, B. & Sun, X. Y. Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol \n                           5(7), 345\u2013352 (2013).","journal-title":"World J Hepatol"},{"key":"8878_CR12","unstructured":"Agarwal, S. V., Reddy, S. S., Dhayal, M. Process for the preparation of metal nanoparticles, US patent (US Patent number US20160263657 A1, Application number US 15\/033,741); EU Patent number WO2015063794 A2; India patent PCT application number PCT\/IN2014\/000695."},{"issue":"10","key":"8878_CR13","doi-asserted-by":"publisher","first-page":"7410","DOI":"10.1021\/la100591h","volume":"26","author":"MN Martin","year":"2010","unstructured":"Martin, M. N., Basham, J. I., Chando, P. & Eah, S. K. Langmuir \n                           26(10), 7410\u20137417 (2010).","journal-title":"Langmuir"},{"issue":"35","key":"8878_CR14","doi-asserted-by":"publisher","first-page":"18250","DOI":"10.1039\/C3RA48047J","volume":"4","author":"SV Agarwal","year":"2014","unstructured":"Agarwal, S. V., Reddy, S. S. & Dhayal, M. Ultra small gold nanoparticles synthesis in aqueous solution and their application in uorometric collagen estimation using biligand functionalisation. RSC Adv \n                           4(35), 18250\u201318256 (2014).","journal-title":"RSC Adv"},{"key":"8878_CR15","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.addr.2009.11.007","volume":"62","author":"CR Patra","year":"2010","unstructured":"Patra, C. R., Bhattacharya, R., Mukhopadhyay, D. & Mukherjee, P. Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev \n                           62, 346\u2013361 (2010).","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"8878_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.taap.2008.12.023","volume":"236","author":"WS Cho","year":"2009","unstructured":"Cho, W. S. et al. Acute toxicity and pharmaco kinetics of 13nm- sized PEG-coated gold nanoparticles. Toxicol Appl Pharmacol \n                           236(1), 16\u201324 (2009).","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"8878_CR17","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.bcp.2011.04.008","volume":"82","author":"TC Kuo","year":"2011","unstructured":"Kuo, T. C., Lu, H. P. & Chao, C. C. K. Thetyrosine kinase inhibitor sorafenib sensitizes hepatocellular carcinoma cells to taxol by suppressing the HURP protein. Biochem Pharmacol \n                           82(2), 184\u2013194 (2011).","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"8878_CR18","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell \n                           144(5), 646\u2013674 (2011).","journal-title":"Cell"},{"issue":"5","key":"8878_CR19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.molmed.2008.03.004","volume":"14","author":"N Gavert","year":"2008","unstructured":"Gavert, N. & Ben-Zeev, A. Epithelial-mesenchymal transition and the invasive potential of tumors. Trends Mol Med \n                           14(5), 199\u2013209 (2008).","journal-title":"Trends Mol Med"},{"key":"8878_CR20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ccr.2009.01.023","volume":"15","author":"C Kudo-Saito","year":"2009","unstructured":"Kudo-Saito, C., Shirako, H., Takeuchi, T. & Kawakami, Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell \n                           15, 195\u2013206 (2009).","journal-title":"Cancer Cell"},{"key":"8878_CR21","first-page":"83","volume":"14","author":"SP Egusquiaguirre","year":"2012","unstructured":"Egusquiaguirre, S. P., Igartua, M., Hern\u00e1ndez, R. M. & Pedraz, J. L. Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. ClinTransl Oncol \n                           14, 83\u201393 (2012).","journal-title":"ClinTransl Oncol"},{"key":"8878_CR22","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.drudis.2012.05.010","volume":"17","author":"P Parhi","year":"2012","unstructured":"Parhi, P., Mohanty, C. & Sahoo, S. K. Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. Drug Discov Today \n                           17, 1044\u20131052 (2012).","journal-title":"Drug Discov Today"},{"issue":"5","key":"8878_CR23","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1021\/nn200007z","volume":"5","author":"F Wang","year":"2011","unstructured":"Wang, F. et al. Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. ACS Nano \n                           5(5), 3679\u20133692 (2011).","journal-title":"ACS Nano"},{"key":"8878_CR24","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1073\/pnas.1421229112","volume":"E","author":"J Conde","year":"2015","unstructured":"Conde, J., Oliva, N. & Artzi, N. Implantable hydrogel embedded dark-gold nano switch as a therapeutic probe to sense and overcome cancer multidrugresistance. PNAS \n                           E, 1278\u20131287 (2015).","journal-title":"PNAS"},{"issue":"3","key":"8878_CR25","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1039\/C0CS00018C","volume":"40","author":"N Khlebtsov","year":"2011","unstructured":"Khlebtsov, N. & Dykman, L. Biodistribution and toxicity of engineered gold nanoparticles: A review of in vitro and in vivo studies. Chem Soc Rev \n                           40(3), 1647\u20131671 (2011).","journal-title":"Chem Soc Rev"},{"issue":"17","key":"8878_CR26","doi-asserted-by":"publisher","first-page":"6700","DOI":"10.1073\/pnas.1214547110","volume":"110","author":"RR Arvizo","year":"2013","unstructured":"Arvizo, R. R. et al. Inhibition of tumor growth and metastasis by a self-therapeutic nanoparticle. PNAS \n                           110(17), 6700\u20136705 (2013).","journal-title":"PNAS"},{"issue":"5","key":"8878_CR27","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1021\/nn200007z","volume":"5","author":"F Wang","year":"2011","unstructured":"Wang, F. et al. Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. ACS Nano \n                           5(5), 3679\u20133692 (2011).","journal-title":"ACS Nano"},{"issue":"2","key":"8878_CR28","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.nano.2011.06.005","volume":"8","author":"YJ Gu","year":"2012","unstructured":"Gu, Y. J., Cheng, J., Man, C. W., Wong, W. T. & Cheng, S. H. Gold-doxorubicin nanoconjugates for overcoming multidrug resistance. Nanomedicine. \n                           8(2), 204\u201311 (2012).","journal-title":"Nanomedicine."},{"key":"8878_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160042","volume":"11","author":"F Li","year":"2016","unstructured":"Li, F. et al. Reducing both Pgp overexpression and drug efflux with anti-cancer gold-paclitaxel nanoconjugates. PLos One \n                           11, e0160042 (2016).","journal-title":"PLos One"},{"key":"8878_CR30","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2174\/1570161112666140226120837","volume":"12","author":"G Bkaily","year":"2014","unstructured":"Bkaily, G., Al-Khoury, J. & Jacques, D. Nuclear membranes Gpcrs: implication in cardiovascular health and diseases. Curr. Vasc. Pharmacol \n                           12, 215\u201322 (2014).","journal-title":"Curr. Vasc. Pharmacol"},{"issue":"2","key":"8878_CR31","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ejpb.2008.08.017","volume":"71","author":"A Khdair","year":"2009","unstructured":"Khdair, A., Handa, H., Mao, G. & Panyam, J. Nanoparticle-mediated combination chemotherapyandphotodynamictherapyovercomes tumordrug resistance in vitro. Eur J Pharm Biopharm \n                           71(2), 214\u2013222 (2009).","journal-title":"Eur J Pharm Biopharm"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-08878-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-08878-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-08878-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T08:43:00Z","timestamp":1671784980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-08878-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,17]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["8878"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-08878-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,17]]},"assertion":[{"value":"4 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"8539"}}